According to the company, Zingo is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous line placements and blood draws in children three to 18 years of age. Zingo works quickly, within one to three minutes, to relieve pain at the needle insertion site, the company said.
Anesiva and its co-promotion partner Sagent Pharmaceuticals are working in tandem to educate caregivers about the importance of addressing peripheral venous access pain in children, and to ensure Zingo availability through hospital pharmacies. Anesiva’s team of 15 hospital-based regional account managers will drive the launch of this product in the US.
Anesiva intends to grow a global brand for Zingo through geographically based license and distribution agreements with companies that have expertise in hospital-based markets in their territories, and has already entered into agreements for several major markets.
Sigma Tau will market Zingo in most major European markets; Medical Futures, is responsible for commercializing Zingo in Canada; and Green Vision will commercialize Zingo in several countries in the Middle East. Anesiva also has established a joint venture in China for the assembly of Zingo devices using US-sourced components.